The experience with the medicamentous treatment of patients with urate urolithiasis

Konstantinova O.V., Shaderkina V.A.

Thirty-four patients with the urate urolithiasis were on the follow-up during 3-6 years: 16 women and 18 men, with age range 31-66 years. In 31 case urolithiasis was recurrent. Three patients were diagnosed with the diabetes mellitus. Function of the kidneys and liver was normal according to the biochemical investigations. The regular investigations included urinalysis, biochemistry of blood and urine, radiological investigations. Medicamentous treatment included allopurinol 0.1 g 3-4 times/day in case of hyperuricemia and / or hyperuricemia, and also blemaren – for urine alkalization. Length of the treatment cycle was 1 month for allopurinol and 1-2.5 months for blemaren. Efficacy was evaluated using two criteria – metabolic and clinical. It was shown that the overall metabolic activity of allopurinol (decrease of normalization of the serum uric acid concentration and 24-hour renal excretion of the uric acid) and blemaren (alkalization of urine) was 98.6%. Allopurinol did not affected the concentrations of other lithogenic substances. Crystalluria of uric acid and oxalates was absent in 100% cases on blemaren. In a subgroup of 12 patients receiving blemaren or combinations blemaren / allopurinol during 1.5-2.5 months aimed at litholysis of the uric acid non-infectious stones (size range 0.8х1.1 cm – 1.8х2.5 cm) have led to the full litholysis of the stones in 75% of patients and partial litholysis in 25% of patients. 

AttachmentSize
Download428.47 KB
urolithiasis, uric acid stones, metabolic disorders, drug treatment, Blemaren, Allopurinol